An announcement from Arctic Bioscience AS ( (DE:9TD) ) is now available.
Arctic Bioscience has published its 2024 annual report, revealing adjustments to its financials due to a NOK 2.34 million cost provision related to a product recall. This adjustment significantly reduced the company’s gross profit and margin for the fourth quarter and the entire year of 2024, reflecting operational challenges and impacting its financial performance.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements based on unique bioactive marine raw materials. The company is developing HRO350, a new oral drug candidate for the treatment of mild-to-moderate psoriasis. Their dietary supplements are sold globally under the brand ROMEGA®.
Average Trading Volume: 89,714
Current Market Cap: NOK92.61M
See more data about 9TD stock on TipRanks’ Stock Analysis page.